Common use of Study Sample Clause in Contracts

Study Sample. Sixty five of the 98 laboratories in the Netherlands eventually responded. Sixteen hospitals, of which the reported list could not be confirmed by a local obstetrician for logistical reasons, were excluded, leaving 49 hospitals available for final analysis. In total, 986 cases were reported by the 49 participating BTLs. The 49 hospitals appeared to be a representative sample of all hospitals in the Netherlands: the sample included three academic hospitals, 19 non-academic teaching hospitals and 27 other hospitals and centres were geographically equally distributed. Furthermore, the proportions of low, moderate and high volume hospitals were comparable to those of the Netherlands. In 162 cases (16.4%), the woman appeared not to have delivered at or around the day of transfusion according to the local birth register, leaving 824 confirmed cases of MOH. During the same period, 727 cases of MOH were reported to ▇▇▇▇▇▇ by the 49 eligible hospitals. After cross matching, we identified 1018 unique cases of MOH from both databases during the study period (Table 1). The estimated number of women not identified through either of the sources, ‘x’ in table 1, was calculated to be 105. Thus the total number of women with MOH is estimated at 1123. Only 727 cases were reported to ▇▇▇▇▇▇, underreporting being estimated at 35% (396/1123). The other way around, 27% (299/1123) of cases would have been missed by only relying on transfusion data from BTLs, after consecutive confirmation by birth registers. Using both sources together would have still yielded an underreporting of 9% (105/1123). The use of a cell saver for auto transfusion was reported to ▇▇▇▇▇▇ in only four cases. This item was not registered by BTLs.

Study Sample. Sixty five of the 98 laboratories in the Netherlands eventually responded. Sixteen hospitals, of which the reported list could not be confirmed by a local obstetrician for logistical reasons, were excluded, leaving 49 hospitals available for final analysis. In total, 986 cases were reported by the 49 participating BTLs. The 49 hospitals appeared to be a representative sample of all hospitals in the Netherlands: the sample included three academic hospitals, 19 non-academic teaching hospitals and 27 other hospitals and centres were geographically equally distributed. Furthermore, the proportions of low, moderate and high volume hospitals were comparable to those of the Netherlands. In 162 cases (16.4%), the woman appeared not to have delivered at or around the day of transfusion according to the local birth register, leaving 824 confirmed cases of MOH. During the same period, 727 cases of MOH were reported to ▇▇▇▇▇▇ LEMMoN by the 49 eligible hospitals. After cross matching, we identified 1018 unique cases of MOH from both databases during the study period (Table 1). The estimated number of women not identified through either of the sources, ‘x’ in table 1, was calculated to be 105. Thus the total number of women with MOH is estimated at 1123. Only 727 cases were reported to ▇▇▇▇▇▇LEMMoN, underreporting being estimated at 35% (396/1123). The other way around, 27% (299/1123) of cases would have been missed by only relying on transfusion data from BTLs, after consecutive confirmation by birth registers. Using both sources together would have still yielded an underreporting of 9% (105/1123). The use of a cell saver for auto transfusion was reported to ▇▇▇▇▇▇ in only four cases. This item was not registered by BTLs.